Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash from Investing Activities (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Cash from Investing Activities for 6 consecutive years, with $35.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities rose 22.29% to $35.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $192.8 million, a 569.29% increase, with the full-year FY2025 number at $192.8 million, up 569.29% from a year prior.
  • Cash from Investing Activities was $35.5 million for Q4 2025 at Relay Therapeutics, down from $39.7 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $75.3 million in Q1 2023 to a low of -$292.7 million in Q4 2021.
  • A 5-year average of -$12.9 million and a median of $32.2 million in 2024 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: tumbled 563.8% in 2021, then skyrocketed 303.24% in 2025.
  • Relay Therapeutics' Cash from Investing Activities stood at -$292.7 million in 2021, then soared by 49.81% to -$146.9 million in 2022, then skyrocketed by 140.61% to $59.7 million in 2023, then tumbled by 51.41% to $29.0 million in 2024, then increased by 22.29% to $35.5 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Cash from Investing Activities are $35.5 million (Q4 2025), $39.7 million (Q3 2025), and $75.1 million (Q2 2025).